Taltz (ixekizumab) — United Healthcare
Non-radiographic Axial Spondyloarthritis
Preferred products
- Cimzia (certolizumab)
- Cosentyx (secukinumab)
- Rinvoq (upadacitinib)
Initial criteria
- Diagnosis of active non-radiographic axial spondyloarthritis
- History of failure to two NSAIDs at maximally indicated doses, each used ≥4 weeks unless contraindicated or adverse effects (document drug/date/duration)
- OR previously treated with a targeted immunomodulator FDA-approved for non-radiographic axial spondyloarthritis (document drug/date/duration; e.g., Cimzia, Cosentyx, Rinvoq)
- History of failure, contraindication, or intolerance to two preferred products: Cimzia, Cosentyx, or Rinvoq
- Patient is not receiving Taltz in combination with another targeted immunomodulator [e.g., Enbrel, Cimzia, Cosentyx, Simponi, Orencia, adalimumab, Xeljanz, Olumiant, Rinvoq]
- Prescribed by or in consultation with a rheumatologist
Approval duration
12 months